Gene · 4191
NIH grants1,254
NIH grants whose papers are about the gene, through NIH's grant-paper links.
121 to 140 of 1,254
Download this page as JSON| Grant | Title | MDH2 papers | Newest fiscal year |
|---|---|---|---|
| R01AG011085 | Ubiquitin‐mediated proteolysis and cell cycle control | 1 | 2025 |
| R01AG076448 | TREM2 Genotype-Informed Drug Repurposing and Combination Therapy Design for Alzheimers Disease | 1 | 2025 |
| R01AG076634 | Phase II randomized controlled trial of benfotiamine in early Alzheimer's Disease | 1 | 2025 |
| R01AI045050 | Characterization of SLE-susceptibility loci on mouse chromosome 1 | 1 | 2025 |
| R01AI056189 | B. thuringiensis crystal proteins as powerful next-generation anthelmintics | 1 | 2025 |
| R01AI110221 | The Cell Biology of HIV-1 Genome Trafficking | 1 | 2025 |
| R01AI125534 | Determinants of apicoplast maintenance in malaria parasites | 1 | 2025 |
| R01AI161015 | Novel Stem Cell Immunotherapy for MDR-Tuberculosis | 1 | 2025 |
| R01AI178692 | Roles of novel cationic lipids in bacterial pathogenesis | 1 | 2025 |
| R01AR066765 | Molecular Etiology of Enchondromatosis | 1 | 2025 |
| R01CA186702 | Mechanisms of epitranscriptomic regulation in cancer | 1 | 2025 |
| R01CA197855 | Roles for Intracellular pH Dynamics in Cancer | 1 | 2025 |
| R01CA252225 | Defining metabolic adaptations within the PDAC "arid" tumor microenvironment | 1 | 2025 |
| R01CA260857 | Multiplexed time domain fluorescence tomography of tumor biomarkers during immunotherapy | 1 | 2025 |
| R01CA260872 | A Phase II and Biomarker Study of Dual VEGF/PD-L1 Blockade in Neoadjuvant Setting in Resectable HCC Patients | 1 | 2025 |
| R01CA262377 | Understanding the role and clinical potential of dominant immune suppressive myeloid-cell responses in human cancer | 1 | 2025 |
| R01CA264248 | Addressing biological and therapeutic gaps in rare neuroendocrine cancer with a novel organoid-based model | 1 | 2025 |
| R01CA268634 | Metabolic Regulation of Glioblastoma Epitranscriptomics | 1 | 2025 |
| R01CA273461 | Sirtuins and Cancer | 1 | 2025 |
| R01CA278050 | Mechanism and therapeutic opportunities of targeting the Tudor domain | 1 | 2025 |
Source NIH's project filesgene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/4191/grants?page=7